Total Payments
$210,590
2024 Payments
$10,693
Companies
61
Transactions
1,483
Medicare Patients
9,719
Medicare Billing
$962,467
Payment Breakdown by Category
Other$166,703 (79.2%)
Food & Beverage$23,401 (11.1%)
Travel$14,403 (6.8%)
Consulting$6,068 (2.9%)
Education$14.67 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $166,703 | 105 | 79.2% |
| Food and Beverage | $23,401 | 1,328 | 11.1% |
| Travel and Lodging | $14,403 | 38 | 6.8% |
| Consulting Fee | $6,068 | 10 | 2.9% |
| Education | $14.67 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $152,744 | 494 | $0 (2024) |
| Mylan Specialty L.P. | $24,435 | 95 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17,985 | 145 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,411 | 126 | $0 (2024) |
| AstraZeneca UK Limited | $1,847 | 11 | $0 (2017) |
| Regeneron Healthcare Solutions, Inc. | $1,051 | 37 | $0 (2024) |
| GENZYME CORPORATION | $884.70 | 35 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $836.49 | 60 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $693.26 | 43 | $0 (2024) |
| United Therapeutics Corporation | $665.31 | 33 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,693 | 177 | GlaxoSmithKline, LLC. ($6,382) |
| 2023 | $32,470 | 206 | GlaxoSmithKline, LLC. ($27,188) |
| 2022 | $25,536 | 162 | GlaxoSmithKline, LLC. ($16,487) |
| 2021 | $26,054 | 150 | GlaxoSmithKline, LLC. ($17,864) |
| 2020 | $28,155 | 131 | GlaxoSmithKline, LLC. ($19,238) |
| 2019 | $76,031 | 239 | GlaxoSmithKline, LLC. ($64,528) |
| 2018 | $7,257 | 210 | Boehringer Ingelheim Pharmaceuticals, Inc. ($4,894) |
| 2017 | $4,393 | 208 | AstraZeneca UK Limited ($1,847) |
All Payment Transactions
1,483 individual payment records from CMS Open Payments — Page 1 of 60
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/18/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $19.19 | General |
| Category: Pulmonology | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: RESPIRATORY | ||||||
| 12/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.75 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: Respiratory | ||||||
| 12/13/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $49.97 | General |
| Category: Immunology | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: RESPIRATORY | ||||||
| 12/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $13.94 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: Respiratory | ||||||
| 12/09/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: Immunology | ||||||
| 12/06/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $30.92 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/06/2024 | Philips North America LLC | (8874) inCourage (Device) | Food and Beverage | Cash or cash equivalent | $26.23 | General |
| Category: Medical Device | ||||||
| 12/04/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $34.18 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/26/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: Inflammation | ||||||
| 11/26/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $11.65 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 11/22/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $29.29 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: Respiratory | ||||||
| 11/13/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: Immunology | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: Respiratory | ||||||
| 11/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPIRIVA RESPIMAT (Drug) | Food and Beverage | In-kind items and services | $27.86 | General |
| Category: RESPIRATORY | ||||||
| 11/07/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $29.48 | General |
| Category: Immunology | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $8.40 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 2,300 | 3,339 | $525,609 | $216,663 |
| 2022 | 18 | 2,392 | 3,640 | $580,535 | $236,440 |
| 2021 | 19 | 2,547 | 4,165 | $657,102 | $270,629 |
| 2020 | 18 | 2,480 | 3,968 | $622,047 | $238,735 |
Total Patients
9,719
Total Services
15,112
Medicare Billing
$962,467
Procedure Codes
80
All Medicare Procedures & Services
80 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 212 | 649 | $94,754 | $40,556 | 42.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 258 | 368 | $78,384 | $34,655 | 44.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 372 | 520 | $75,400 | $34,180 | 45.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 165 | 214 | $86,884 | $29,322 | 33.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 81 | 157 | $45,216 | $20,605 | 45.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 133 | 133 | $43,491 | $16,700 | 38.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 161 | 273 | $21,294 | $10,715 | 50.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 31 | 88 | $18,304 | $8,273 | 45.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 47 | 47 | $12,925 | $4,831 | 37.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 35 | 40 | $7,240 | $2,702 | 37.3% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 119 | 119 | $8,449 | $2,458 | 29.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 21 | 21 | $4,494 | $1,695 | 37.7% |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | Office | 2023 | 53 | 59 | $6,313 | $1,651 | 26.1% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 163 | 168 | $4,200 | $1,574 | 37.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 12 | 12 | $3,456 | $1,355 | 39.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 11 | 15 | $3,840 | $1,312 | 34.2% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 164 | 169 | $3,042 | $1,178 | 38.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 136 | 139 | $4,170 | $1,118 | 26.8% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 50 | 71 | $1,988 | $1,038 | 52.2% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 64 | 65 | $1,105 | $417.30 | 37.8% |
| 99407 | Smoking and tobacco use intensive counseling, more than 10 minutes | Office | 2023 | 12 | 12 | $660.00 | $327.72 | 49.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 222 | 251 | $101,906 | $39,273 | 38.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 219 | 658 | $96,068 | $37,107 | 38.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 253 | 374 | $79,662 | $35,565 | 44.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 354 | 484 | $70,180 | $31,079 | 44.3% |
About Dr. Bobby Shah, MD
Dr. Bobby Shah, MD is a Pulmonary Disease healthcare provider based in Chesterfield, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/14/2007. The National Provider Identifier (NPI) number assigned to this provider is 1538340930.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bobby Shah, MD has received a total of $210,590 in payments from pharmaceutical and medical device companies, with $10,693 received in 2024. These payments were reported across 1,483 transactions from 61 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($166,703).
As a Medicare-enrolled provider, Shah has provided services to 9,719 Medicare beneficiaries, totaling 15,112 services with total Medicare billing of $962,467. Data is available for 4 years (2020–2023), covering 80 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Chesterfield, MO
- Active Since 11/14/2007
- Last Updated 02/23/2017
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1538340930
Products in Payments
- TRELEGY ELLIPTA (Drug) $84,027
- NUCALA (Biological) $32,717
- Yupelri (Drug) $19,129
- ANORO (Drug) $13,316
- YUPELRI (Drug) $5,200
- DUPIXENT (Biological) $1,778
- ANORO ELLIPTA (Drug) $1,411
- OFEV (Drug) $861.52
- STIOLTO RESPIMAT (Drug) $797.26
- ELIQUIS (Drug) $735.23
- XARELTO (Drug) $693.26
- TEZSPIRE (Biological) $610.35
- Arikayce (Drug) $564.02
- BREZTRI (Drug) $497.78
- SMARTVEST (Device) $473.78
- SYMBICORT (Drug) $403.14
- ORENITRAM (Drug) $381.61
- ENTRESTO (Drug) $379.68
- UPTRAVI (Drug) $350.01
- Prolastin-C Liquid (Biological) $326.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Chesterfield
Kristen Fisher, M.d, M.D
Pulmonary Disease — Payments: $14,948
Pulmonary Disease $14,948
John Best, Md, MD
Pulmonary Disease — Payments: $2,776
Pulmonary Disease $2,776
Dr. Steven Brown, M.d, M.D
Pulmonary Disease — Payments: $614.58
Pulmonary Disease $614.58
Adnan Habib, Md, MD
Pulmonary Disease
Pulmonary Disease
Dr. Rhody Eisenstein, Md, MD
Pulmonary Disease
Pulmonary Disease